GLPG1690

Unassigned

New Medicines

Idiopathic pulmonary fibrosis

Information

New molecular entity
Galapagos
Galapagos

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Yes
Yes

Category

Autotaxin (ectonucleotide pyrophosphatase/phosphodiesterase 2, NPP2 or ENPP2) inhibitor
Idiopathic Pulmonary Fibrosis (IPF) is the most common interstitial lung disease, with an estimated incidence in the UK of around 7.44 per 100,000 population [2].
Idiopathic pulmonary fibrosis
Oral